AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26483177
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of omalizumab
Trial: 24567516
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg once weekly (CIL1W) + PFE
Trial: 24567516
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg twice weekly (CIL2W) + PFE
Trial: 16213325
Drug: CsA-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-based treatment (n = 73)
Trial: 16213325
Drug: Tacrolimus-based treatment
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus-based treatment (n = 47)
Trial: 8574272
Drug: ICI D7114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI D7114 (150 mg/day)
Trial: 23677386
Drug: In SHAPE
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In SHAPE program (one year of weekly sessions with a fitness trainer plus a fitness club membership)
Trial: 19264687
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg administered in five monthly infusions)
Trial: 17889778
Drug: Intracameral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral cefuroxime treatment
Trial: 9643742
Drug: rhGH (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (2 IU daily)
Trial: 3169118
Drug: cimetidine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (1.2 g daily)
Trial: 3169118
Drug: ranitidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (0.3 g daily)
Trial: 29782479
Drug: Multicomponent balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent balance and resistance training intervention (once weekly supervised group sessions with home sessions encouraged twice weekly)
Trial: 29920171
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of LARC
Trial: 21876061
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg micafungin
Trial: 21876061
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg micafungin
Trial: 21876061
Drug: Micafungin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (both doses)
Trial: 10729306
Drug: Sub‐Tenon's block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 + 30 IU/ml of hyaluronidase
Trial: 10729306
Drug: Sub‐Tenon's block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub‐Tenon's block with 3 ml lignocaine 2%/adrenaline 1:200 000 alone
Trial: 1390305
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (rIFN alfa‐2a + VLB)
Trial: 1390305
Drug: Monotherapy (rIFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (rIFN alfa‐2a)
Trial: 3902068
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase infusion
Trial: 29595659
Drug: Radial artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial artery pressure pulse wave treatment in stroke patients with hemiplegia
Trial: 29081178
Drug: Weight management
RxNorm normalized name: Estroven Weight Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight management guidance and adjusted diuretic drugs regimen based on body weight changes
Trial: 26314275
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg fortnightly after induction)
Trial: 26314275
Drug: Thiopurines (azathioprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopurines (azathioprine 2 mg/kg/day or mercaptopurine 1.5 mg/kg/day)
Trial: 23216710
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) thromboprophylaxis
Trial: 23216710
Drug: Strong IgG
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strong IgG antibodies (≥ 1.0 OD units and ≥ 2× baseline)
Trial: 23216710
Drug: No strong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No strong IgG antibodies
Trial: 23216710
Drug: Postoperative anti-PF4/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative anti-PF4/heparin IgG responses
Trial: 21624100
Drug: Adrenaline (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (0.4 μg min m(‐2))
Trial: 18945995
Drug: Cinacalcet and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet and low-dose vitamin D (Cinacalcet-D)
Trial: 16467100
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg plus sirolimus 5 mg (not on EIAEDs)
Trial: 16467100
Drug: Gefitinib 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 1000 mg plus sirolimus 10 mg (on EIAEDs)
Trial: 11314676
Drug: Oral cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cocaine (100 mg/70 kg)
Trial: 3809244
Drug: L-tryptophan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (4 tablets of 500 mg/day for 14 days)
Trial: 3809244
Drug: Phenylalanine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine (4 tablets of 500 mg/day for 14 days)
Trial: 3809244
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 placebo tablets/day for 14 days)
Trial: 27678426
Drug: Low advanced
RxNorm normalized name: ALCOHOL 75 in 100 TOPICAL CLOTH [Mellow advanced alcohol wipes 50wipes 01]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low advanced glycation end products diet (L‐dAGEs)
Trial: 11709789
Drug: BBG2Na (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBG2Na (all doses)
Trial: 9051434
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 0.14 mg/nostril twice daily (0.56 mg/day)
Trial: 8091174
Drug: Lidocaine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2.0 ml 2%)
Trial: 8091174
Drug: Articaine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine (2.0 ml 4%)
Trial: 3592320
Drug: 12-hour cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-hour cefazolin (4 intravenous injections of 1 g cefazolin over 12 hours)
Trial: 3592320
Drug: 36-hour cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36-hour cefazolin (12 doses over 36 hours)
Trial: 12486618
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg twice daily
Trial: 29502160
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) for BMS
Trial: 29502160
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) for SOB
Trial: 30102967
Drug: Lurasidone 20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-60 mg/day
Trial: 23883379
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg semagacestat
Trial: 26948580
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg semagacestat
Trial: 19655819
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 20/25 mg/day
Trial: 19655819
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 40/12.5 mg/day
Trial: 19655819
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with olmesartan medoxomil/HCTZ 40/25 mg/day
Trial: 19655819
Drug: HCTZ 12.5
RxNorm normalized name: HCTZ 12.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 12.5 or 25 mg/day
Trial: 19655819
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 10, 20, or 40 mg/day
Trial: 16273313
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) + BCNU + standard radiation therapy (SRT)
Trial: 16273313
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) + BCNU + accelerated radiation therapy (ART)
Trial: 16273313
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) + standard radiation therapy (SRT)
Trial: 16273313
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) + accelerated radiation therapy (ART)
Trial: 11259892
Drug: Mepivacaine 1%
RxNorm normalized name: mepivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 1% (1 mL/kg)
Trial: 11259892
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% (1 mL/kg)
Trial: 11259892
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of mepivacaine 1% and bupivacaine 0.25% (0.5 mL/kg each)
Trial: 26214725
Drug: Riluzole 50
RxNorm normalized name: riluzole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole 50 mg twice a day
Trial: 22233243
Drug: Trauma Affect
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Trial: 19469601
Drug: Supportive Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Group Therapy (SGT)
Trial: 21301135
Drug: Midodrine hydrochloride
RxNorm normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine hydrochloride plus conventional therapy
Trial: 21301135
Drug: Metoprolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol plus conventional therapy
Trial: 12183280
Drug: Voriconazole at
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole at 10.4 +/- 4.3 micro g/ml
Trial: 11477859
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus Chinese herbal medicine
Trial: 2514651
Drug: Cicletanine 50
RxNorm normalized name: cicletanine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 50 mg daily for 3 months
Trial: 2514651
Drug: Cicletanine 100
RxNorm normalized name: cicletanine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 100 mg daily for 3 months
Trial: 26705233
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate Gel (SHG group)
Trial: 23117218
Drug: Adjuvant Occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Occupational Therapy (OT)
Trial: 21048770
Drug: diet+PS (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet+PS (2 g/day of phytosterols)
Trial: 18506005
Drug: RB006 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB006 (15 mg)
Trial: 18506005
Drug: RB006 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB006 (30 mg)
Trial: 18506005
Drug: RB006 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB006 (50 mg)
Trial: 18506005
Drug: RB006 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB006 (75 mg)
Trial: 7979564
Drug: Pulsatile oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile oxytocin infusion
Trial: 8970215
Drug: Amoxicillin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (20 mg/kg once daily)
Trial: 7982173
Drug: OK-432 (intratumoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (intratumoral injection)
Trial: 6385693
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and Tobramycin with peak levels of 7 micrograms/ml or greater
Trial: 6385693
Drug: Amikacin with
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin with peak levels of 28 micrograms/ml or greater
Trial: 6385693
Drug: Overall mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall mean peak levels of 6 micrograms/ml or greater for Gentamicin and Tobramycin
Trial: 6385693
Drug: Overall mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall mean peak levels of 24 micrograms/ml or greater for Amikacin
Trial: 29368187
Drug: Fluvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin with green tea extract (GTE) containing 150 mg of EGCG
Trial: 11220429
Drug: Dexamethasone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2.5 mg
Trial: 25603389
Drug: Dexamethasone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5.0 mg
Trial: 25603389
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.0 mg dexamethasone)
Trial: 24411757
Drug: Orlistat and
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat and sibutramine treatment
Trial: 18188033
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg twice daily)
Trial: 18188033
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g three times a day)
Trial: 16763848
Drug: ADCON‐L Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCON‐L Gel (ALG)
Trial: 15230300
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose glucocorticoids and immunosuppressive agents
Trial: 12439362
Drug: Aggressive saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive saline hydration with the aim of keeping urine output over 150 mL/hour
Trial: 12439362
Drug: Low-osmolality contrast
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolality contrast agents with minimal volume
Trial: 12439362
Drug: Dopamine DA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine DA1 agonist fenoldopam
Trial: 7962669
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg S(‐)‐atenolol (SATN)
Trial: 7962669
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg racemic atenolol (RSATN)
Trial: 8949760
Drug: Neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron therapy
Trial: 26202325
Drug: Robot-supported upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-supported upper limb training (3 weekly sessions of 30 min for 8 weeks)
Trial: 18194307
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with bypassing agents (FEIBA and NovoSeven)
Trial: 18194307
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with one bypassing agent (effective)
Trial: 17165494
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus antiasthma agents
Trial: 17165494
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antiasthma agents only)
Trial: 53554
Drug: Cimetidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 0.8 g/day
Trial: 7015989
Drug: Glycopyrrolate 4
RxNorm normalized name: GLYCOPYRROLATE 4 mg in 20 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 4 mg/day
Trial: 30073290
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily for 8 weeks
Trial: 16606645
Drug: Single DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single DMARD treatment with or without prednisolone (single group)
Trial: 16606645
Drug: Combination DMARD
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DMARD treatment with prednisolone (combination group)
Trial: 10385132
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 40 mg, three times daily orally for 2 days
Trial: 1760831
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sustained-release IS-5-MN
Trial: 1760831
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg sustained-release IS-5-MN
Trial: 1760831
Drug: Elantan Long
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elantan Long (50 mg sustained-release IS-5-MN)
Trial: 6760653
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 100 mg twice daily for 12 weeks
Trial: 24439984
Drug: Trandolapril 22
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril 22 mg daily
Trial: 16873938
Drug: CoQ(10) supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) supplementation (100 mg tid for 4 weeks)
Trial: 12424684
Drug: Cefixime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (2 mg/kg bodyweight)
Trial: 30726689
Drug: Omadacycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline (100 mg IV every 12 hours for two doses, then 100 mg IV every 24 hours; transition to oral 300 mg every 24 hours after 3 days allowed)
Trial: 30726689
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg IV every 12 hours; transition to oral 600 mg every 12 hours after 3 days allowed)
Trial: 29856291
Drug: Octreotide used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide used when other therapies failed; previously prescribed octreotide for this clinical indication.
Trial: 26563147
Drug: Motivational Interviewing/Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing/Cognitive Behavioral Therapy (MI-CBT)
Trial: 23127770
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy (HDRB) boost
Trial: 23127770
Drug: Adjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant androgen suppression, bisphosphonates, and increasing EBRT dose
Trial: 20927698
Drug: Zonisamide (400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (400-600 mg/day tapering to 100-300 mg/day)
Trial: 20927698
Drug: Diazepam (130-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (130-50 mg/day tapering to 5-15 mg/day)
Trial: 18372685
Drug: Daily exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposure to a +Gz acceleration gradient
Trial: 15791505
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of fluoroquinolone prophylaxis
Trial: 3016764
Drug: Subjective effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective effects measures (Addiction Research Center Inventory, Single Dose Questionnaire, Visual Analog Scale)
Trial: 26002761
Drug: Rotigotine (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (dopamine agonist patch with 24-hour action)
Trial: 20079321
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg adalimumab
Trial: 16979327
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus (petal) 30 mg/day (BD)
Trial: 15580395
Drug: 5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. in fasted state
Trial: 15580395
Drug: 5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. after semiliquid test meal